Current Treatment of Osteosarcoma

REFERENCES

• Marcove R. C., Mike V., Hajek J. V., et al. Osteogenic Sarcoma under the Age of Twenty-One: A Review of One Hundred Forty-Five Operative Cases. J. Bone Joint Surg. [Am.] 1970; 52: 411–423
   PubMed Web of Science ®Google Scholar
• Van Trommel M. F., Kroon H. M., Bloem J. L., et al. MR Imaging Based Strategies in Limb Salvage Surgery for Osteosarcoma of the Distal Femur. Skeletal Radiol. 1997; 26: 636–641
   PubMed Web of Science ®Google Scholar
• Bhagia S. M., Grimer R. J., Davies A. M., et al. Scintigraphically Negative Skip Metastasis in Osteosarcoma. Eur. Radiol. 1997; 7: 1446–1448
   PubMed Web of Science ®Google Scholar
• Gebhardt M. C., Ready J. E., Mankin H. J. Tumors About the Knee in Children. Clin. Orthop. 1990; 255: 86–110
   PubMedGoogle Scholar
• Picci P., Sangiorgi L., Bahamonde L., et al. Risk Factors for Local Recurrences After Limb-Salvage Surgery for High-Grade Osteosarcoma of the Extremities. Ann. Oncol. 1997; 8: 899–903
   PubMed Web of Science ®Google Scholar
• Brostrom L. A., Harris M. A., Simon M. A., et al. The Effect of Biopsy on Survival of Patients with Osteosarcoma. J. Bone Joint Surg. [Br.] 1979; 61-B(2)209–212
   PubMed Web of Science ®Google Scholar
• Mankin H. J., Lange T. A., Spanier S. S. The Hazards of Biopsy in Patients with Malignant Primary Bone and Soft-Tissue Tumors. J. Bone Joint Surg. [Am.] 1982; 64: 1121–1127
   PubMed Web of Science ®Google Scholar
• Mankin H. J., Mankin C. J., Simon M. A. The Hazards of the Biopsy, Revisited. J. Bone Joint Surg. [Am.] 1996; 78: 656–663
   PubMed Web of Science ®Google Scholar
• Alkallaf S., Voisin M. C., Desbois J. C., et al. Local Relapses Following Limb Sparing Salvage Surgery for Osteosarcoma. Prognostic Factors and Influence of Chemotherapy. Proc. Am. Soc. Clin. Oncol. 1996; 15: 526, (abstract 1700)
   Google Scholar
• Scranton P. E., Jr, DeCicco F. A., Totten R. S., et al. Prognostic Factors in Osteosarcoma. A Review of 20 Years’ Experience at the University of Pittsburgh Health Center Hospitals. Cancer 1975; 36: 2179–2191
   PubMed Web of Science ®Google Scholar
• Uribe-Botero G., Russell W. O., Sutow W. W., et al. Primary Osteosarcoma of Bone. Clinicopathologic Investigation of 243 Cases, with Necropsy Studies in 54. Am. J. Clin. Pathol. 1977; 67: 427–435
   PubMed Web of Science ®Google Scholar
• Goorin A. M., Perez-Atayde A., Gebhardt M., et al. Weekly High-Dose Methotrexate and Doxorubicin for Osteosarcoma: The Dana-Farber Cancer Institute/The Children’s Hospital—Study III. J. Clin. Oncol. 1987; 5: 1178–1184
   PubMed Web of Science ®Google Scholar
• Jaffe N., Raymond A. K., Ayala A., et al. Effect of Cumulative Courses of Intraarterial Cis-Diamminedichloroplatin-II on the Primary Tumor in Osteosarcoma. Cancer 1989; 63: 63–67
   PubMed Web of Science ®Google Scholar
• Hudson M., Jaffe M. R., Jaffe N., et al. Pediatric Osteosarcoma: Therapeutic Strategies, Results, and Prognostic Factors Derived from a 10-Year Experience. J. Clin. Oncol. 1990; 8: 1988–1997
   PubMed Web of Science ®Google Scholar
• Petrilli A. S., Gentil F. C., Epelman S., et al. Increased Survival, Limb Preservation, and Prognostic Factors for Osteosarcoma. Cancer 1991; 68: 733–737
   PubMed Web of Science ®Google Scholar
• Werner M., Fuchs N., Salzer-Kuntschik M., et al. Therapy-Induced Changes in Osteosarcoma After Neoadjuvant Chemotherapy (COSS 86 Therapy Study). Correlation Between Morphologic Findings and Clinical Follow-Up. Pathologe 1996; 17: 35–43
   PubMed Web of Science ®Google Scholar
• Bacci G., Ferrari S., Delepine N., et al. Predictive Factors of Histologic Response to Primary Chemotherapy in Osteosarcoma of the Extremity: Study of 272 Patients Preoperatively Treated with High-Dose Methotrexate, Doxorubicin, and Cisplatin. J. Clin. Oncol. 1998; 16: 658–663
   PubMed Web of Science ®Google Scholar
• Scully S. P., Temple H. T., O’Keefe R. J., et al. The Surgical Treatment of Patients with Osteosarcoma Who Sustain a Pathologic Fracture. Clin. Orthop. 1996; 324: 227–232
   PubMedGoogle Scholar
• Rosen G., Huvos A. G., Marcove R., et al. Telangiectatic Osteogenic Sarcoma. Improved Survival with Combination Chemotherapy. Clin. Orthop. 1986; 207: 164–173
   PubMedGoogle Scholar
• Bacci G., Pignatti G., Dallari D., et al. Primary Chemotherapy and Delayed Surgery (Neoadjuvant Chemotherapy) for Telangiectatic Osteogenic Sarcoma of the Extremities. J. Chemother. 1989; 1: 190–196
   PubMed Web of Science ®Google Scholar
• Pignatti G., Bacci G., Picci P., et al. Telangiectatic Osteogenic Sarcoma of the Extremities. Results in 17 Patients Treated with Neoadjuvant Chemotherapy. Clin. Orthop. 1991; 270: 99–106
   PubMedGoogle Scholar
• Bacci G., Picci P., Ferrari S., et al. Primary Chemotherapy and Delayed Surgery for Non-Metastatic Telangiectatic Osteosarcoma of the Extremities. Results in 28 Patients. Eur. J. Cancer 1994; 30A: 620–626
   PubMed Web of Science ®Google Scholar
• Sim F. H., Unni K. K., Beabout J. W., et al. Osteosarcoma with Small Cells Simulating Ewing’s Tumor. J. Bone Joint Surg. [Am.] 1979; 61: 207–215
   PubMed Web of Science ®Google Scholar
• Martin S. E., Dwyer A., Kissane J. M., et al. Small-cell Osteosarcoma. Cancer 1982; 50: 990–996
   PubMed Web of Science ®Google Scholar
• Ayala A. G., Ro J. Y., Raymond A. K., et al. Small Cell Osteosarcoma. A Clinicopathologic Study of 27 Cases. Cancer 1989; 64: 2162–2173
   PubMed Web of Science ®Google Scholar
• Nakajima H., Sim F. H., Bond J. R., et al. Small Cell Osteosarcoma of Bone. Review of 72 Cases. Cancer 1997; 79: 2095–2106
   PubMed Web of Science ®Google Scholar
• Bacci G., Ferrari S., Bertoni F., et al. Neoadjuvant Chemotherapy for Osseous Malignant Fibrous Histiocytoma of the Extremity: Results in 18 Cases and Comparison with 112 Contemporary Osteosarcoma Patients Treated with the Same Chemotherapy Regimen. J. Chemother. 1997; 9: 293–299
   PubMed Web of Science ®Google Scholar
• Picci P., Bacci G., Ferrari S., et al. Neoadjuvant Chemotherapy in Malignant Fibrous Histiocytoma of Bone and in Osteosarcoma Located in the Extremities: Analogies and Differences Between the Two Tumors. Ann. Oncol. 1997; 8: 1107–1115
   PubMed Web of Science ®Google Scholar
• Oliviera P., Ayala A., Benjamin R., et al. Preoperative Intraarterial Cisplatin Based Chemotherapy in the Management of Periosteal Osteosarcoma. Proc. Am. Soc. Clin. Oncol. 1994; 13: 473, (abstract 1647)
   Google Scholar
• Sheth D. S., Yasko A. W., Raymond A. K., et al. Conventional and Dedifferentiated Parosteal Osteosarcoma. Diagnosis, Treatment, and Outcome. Cancer 1996; 78: 2136–2145
   PubMed Web of Science ®Google Scholar
• Jeffree G. M., Price C. H., Sissons H. A. The Metastatic Patterns of Osteosarcoma. Br. J. Cancer 1975; 32: 87–107
   PubMed Web of Science ®Google Scholar
• Siemers E., Seeber S., Hoffken K., et al. Results of Cytostatic Therapy with Cyclophosphamide, Vincristine, Adriamycin and DTIC (CYVADIC) in Localized and Metastasized Osteosarcoma. A Retrospective Analysis. Onkologie 1980; 3: 78–84
   PubMed Web of Science ®Google Scholar
• Eilber F. R., Rosen G. Adjuvant Chemotherapy for Osteosarcoma. Semin. Oncol. 1989; 16: 312–322
   PubMed Web of Science ®Google Scholar
• Cassano W. F., Graham-Pole J., Dickson N. Etoposide, Cyclophosphamide, Cisplatin, and Doxorubicin as Neoadjuvant Chemotherapy for Osteosarcoma. Cancer 1991; 68: 1899–1902
   PubMed Web of Science ®Google Scholar
• Ferrar S., Avella M., Briccoli A., et al. Primary Chemotherapy and Delayed Surgery for Osteosarcoma of the Extremities with Synchronous Metastases. Ann. Oncol. 1992; 3(suppl 2)S39–S41
   PubMedGoogle Scholar
• Bacci G., Picci P., Briccoli A., et al. Osteosarcoma of the Extremity Metastatic at Presentation: Results Achieved in 26 Patients Treated with Combined Therapy (Primary Chemotherapy Followed by Simultaneous Resection of the Primary and Metastatic Lesions). Tumori 1992; 78: 200–206
   PubMed Web of Science ®Google Scholar
• Bacci G., Briccoli A., Ferrari S., et al. Osteosarcoma of the Extremities Metastatic at Presentation. Results Obtained with Primary Chemotherapy Followed by Simultaneous Resection of the Primary and Metastatic Lesion. Minerva Chir. 1993; 48: 35–45
   PubMedGoogle Scholar
• Meyers P. A., Heller G., Healey J. H., et al. Osteogenic Sarcoma with Clinically Detectable Metastasis at Initial Presentation. J. Clin. Oncol. 1993; 11: 449–453
   PubMed Web of Science ®Google Scholar
• Bacci G., Mercuri M., Briccoli A., et al. Osteogenic Sarcoma of the Extremity with Detectable Lung Metastases at Presentation. Results of Treatment of 23 Patients with Chemotherapy Followed by Simultaneous Resection of Primary and Metastatic Lesions. Cancer 1997; 79: 245–254
   PubMed Web of Science ®Google Scholar
• Bacci G., Briccoli A., Mercuri M., et al. Osteosarcoma of the Extremities with Synchronous Lung Metastases: Long-Term Results in 44 Patients Treated with Neoadjuvant Chemotherapy. J. Chemother. 1998; 10: 69–76
   PubMed Web of Science ®Google Scholar
• Goorin A. M., Abelson H. T., Frei E. Osteosarcoma: Fifteen Years Later. N. Engl. J. Med. 1985; 313: 1637–1643
   PubMed Web of Science ®Google Scholar
• Gilbert J. C., Powell D. M., Hartman G. E., et al. Video-Assisted Thoracic Surgery (VATS) for Children with Pulmonary Metastases from Osteosarcoma. Ann. Surg. Oncol. 1996; 3: 539–542
   PubMed Web of Science ®Google Scholar
• Goorin A. M., Delorey M. J., Lack E. E., et al. Prognostic Significance of Complete Surgical Resection of Pulmonary Metastases in Patients with Osteogenic Sarcoma: Analysis of 32 Patients. J. Clin. Oncol. 1985; 2: 425–431
   Web of Science ®Google Scholar
• Meyer W. H., Schell M. J.H., Kumar A. P.M., et al. Thoracotomy for Pulmonary Metastatic Osteosarcoma. An Analysis of Prognostic Indicators of Survival. Cancer 1987; 59: 374–379
   PubMed Web of Science ®Google Scholar
• Winkler K., Beron G., Schellong G., et al. Cooperative Osteosarcoma Study COSS-77: Results After 4 Years. Klin. Padiatr. 1982; 194: 251–256
   PubMed Web of Science ®Google Scholar
• Raymond A. K., Chawla S. P., Carrasco C. H., et al. Osteosarcoma Chemotherapy Effect: A Prognostic Factor. Semin. Diagn. Pathol. 1987; 4: 212–236
   PubMed Web of Science ®Google Scholar
• Bielack S., Beck J., Delling G., et al. Neoadjuvant Chemotherapy of Osteosarcoma. Results of the Cooperative Studies COSS-80 and COSS-82 After 7 and 5 Years. Klin. Padiatr. 1989; 201: 275–284
   PubMed Web of Science ®Google Scholar
• Quintana J., Beresi V., DelPozo H., et al. Intra-Arterial Cisplatin Given Prior to Surgery in Osteosarcoma: Grade of Necrosis and Size of Tumor as Major Prognostic Factors. Am. J. Pediatr. Hematol. Oncol. 1991; 13: 269–273
   PubMedGoogle Scholar
• Jaffe N., Smith D., Jaffe M. R., et al. Intraarterial Cisplatin in the Management of Stage IIB Osteosarcoma in the Pediatric and Adolescent Age Group. Clin. Orthop. 1991; 270: 15–21
   PubMed Web of Science ®Google Scholar
• Rehan N., Bieling P., Winkler P., et al. The Prognostic Significance of Tumor Volume in Osteosarcoma with Neoadjuvant Chemotherapy. Klin. Padiatr. 1993; 205: 200–209
   PubMed Web of Science ®Google Scholar
• Bieling P., Rehan N., Winkler P., et al. Tumor Size and Prognosis in Aggressively Treated Osteosarcoma. J. Clin. Oncol. 1996; 14: 848–858
   PubMed Web of Science ®Google Scholar
• Link M. P., Goorin A. M., Horowitz M., et al. Adjuvant Chemotherapy of High-Grade Osteosarcoma of the Extremity. Updated Results of the Multi-Institutional Osteosarcoma Study. Clin. Orthop. 1991; 270: 8–14
   PubMed Web of Science ®Google Scholar
• Glasser D. B., Lane J. M., Huvos A. G., et al. Survival, Prognosis, and Therapeutic Response in Osteogenic Sarcoma. The Memorial Hospital Experience. Cancer 1992; 69: 698–708
   PubMed Web of Science ®Google Scholar
• Provisor A. J., Ettinger L. J., Nachman J. B., et al. Treatment of Nonmetastatic Osteosarcoma of the Extremity with Preoperative and Postoperative Chemotherapy: A Report from the Children’s Cancer Group. J. Clin. Oncol. 1997; 15: 76–84
   PubMed Web of Science ®Google Scholar
• Saeter G., Bruland O. S., Folleras G., et al. Extremity and Non-Extremity High-Grade Osteosarcoma—the Norwegian Radium Hospital Experience During the Modern Chemotherapy Era. Acta Oncol. 1996; 35(suppl 8)129–134
   PubMedGoogle Scholar
• Pylkkanen L., Aho A. J., Ekfors T., et al. Treatment Results of Osteogenic Sarcoma. An Evaluation of 36 Patients Treated During 30-Year Period in South-Western Finland. Eur. J. Surg. Oncol. 1997; 23: 54–58
   PubMedGoogle Scholar
• Van Es R. J., Keus R. B., van der Waal I., et al. Osteosarcoma of the Jaw Bones. Long-Term Follow Up of 48 Cases. Int. J. Oral Maxillofac. Surg. 1997; 26: 191–197
   PubMed Web of Science ®Google Scholar
• Meyers P. A., Heller G., Healey J., et al. Chemotherapy for Nonmetastatic Osteogenic Sarcoma: The Memorial Sloan-Kettering Experience. J. Clin. Oncol. 1992; 10: 5–15
   PubMed Web of Science ®Google Scholar
• Pochanugool L., Subhadharaphandou T., Dhanachai M., et al. Prognostic Factors Among 130 Patients with Osteosarcoma. Clin. Orthop. 1997; 345: 206–214
   PubMedGoogle Scholar
• Ferrari S., Bacci G., Picci P., et al. Long-Term Follow-Up and Post-Relapse Survival in Patients with Non-Metastatic Osteosarcoma of the Extremity Treated with Neoadjuvant Chemotherapy. Ann. Oncol. 1997; 8: 765–771
   PubMed Web of Science ®Google Scholar
• Bacci G., Picci P., Ferrari S., et al. Prognostic Significance of Serum Alkaline Phosphatase Measurements in Patients with Osteosarcoma Treated with Adjuvant or Neoadjuvant Chemotherapy. Cancer 1993; 71: 1224–1230
   PubMed Web of Science ®Google Scholar
• Herson J., Sutow W. W., Elder K., et al. Adjuvant Chemotherapy in Nonmetastatic Osteosarcoma: A Southwest Oncology Group Study. Med. Pediatr. Oncol. 1980; 8: 343–352
   PubMedGoogle Scholar
• Bacci G., Avella M., Capanna R., et al. Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma of the Extremities: Preliminary Results in 131 Cases Treated Preoperatively with Methotrexate and Cisdiamminoplatinum. Ital. J. Orthop. Traumatol. 1988; 14: 23–39
   PubMedGoogle Scholar
• Look A. T., Douglass E. D., Meyer W. H. Clinical Importance of Near-Diploid Tumor Stem Lines in Patients with Osteosarcoma of an Extremity. N. Engl. J. Med. 1988; 318: 1567–1572
   PubMed Web of Science ®Google Scholar
• Feugeas O., Guriec N., Babin-Boilletot A., et al. Loss of Heterozygosity of the RB Gene Is a Poor Prognostic Factor in Patients with Osteosarcoma. J. Clin. Oncol. 1996; 14: 467–472
   PubMed Web of Science ®Google Scholar
• Trieb K., Lechleitner T., Lang S., et al. Heat Shock Protein 72 Expression in Osteosarcomas Correlates with Good Response to Neoadjuvant Chemotherapy. Hum. Pathol. 1998; 29: 1050–1055
   PubMed Web of Science ®Google Scholar
• Onda M., Matsuda S., Higaki S., et al. ErbB-2 Expression Is Correlated with Poor Prognosis for Patients with Osteosarcoma. Cancer 1996; 77: 71–78
   PubMed Web of Science ®Google Scholar
• Copeland M. M., Sutow W. W. Osteogenic Sarcoma: The Past, Present, and Future. Int. Adv. Surg. Oncol. 1979; 2: 177–200
   PubMedGoogle Scholar
• Sinks L. F., Mindell E. R. Chemotherapy of Osteosarcoma. Clin. Orthop. 1975; 111: 101–104
   PubMedGoogle Scholar
• Campanacci M., Bacci G., Pagani P., et al. Multiple-Drug Chemotherapy for the Primary Treatment of Osteosarcoma of the Extremities. J. Bone Joint Surg. [Br.] 1980; 62-B: 93–101
   PubMed Web of Science ®Google Scholar
• Jurgens H., Rosen G. Combination Chemotherapy in Osteogenic Sarcoma: The Memorial Sloan-Kettering Cancer Center Experience. Klin. Padiatr. 1980; 192: 123–129
   PubMed Web of Science ®Google Scholar
• Sutow W. W. Multidrug Chemotherapy in Osteosarcoma. Clin. Orthop. 1980; 153: 67–72
   PubMedGoogle Scholar
• Ettinger L. J., Douglass H. O., Jr., Higby D. J., et al. Adjuvant Adriamycin and Cis-Diamminedichloroplatinum (Cis-Platinum) in Primary Osteosarcoma. Cancer 1981; 47: 248–254
   PubMed Web of Science ®Google Scholar
• Jaffe N., Goorin A., Link M., et al. High-Dose Methotrexate in Osteogenic Sarcoma Adjuvant Chemotherapy and Limb Salvage Results. Cancer Treat. Rep. 1981; 65(suppl 1)99–106
   PubMedGoogle Scholar
• Bullimore J. A. UK and European Trials of Chemotherapy in Osteosarcoma. Cancer Treat. Rep. 1981; 65(suppl 1)113–117
   PubMedGoogle Scholar
• Lange B., Kramer S., Gregg J. R., et al. High-Dose Methotrexate and Adriamycin in Osteogenic Sarcoma: The Children’s Hospital of Philadelphia Study. Am. J. Clin. Oncol. 1982; 5: 3–8
   PubMed Web of Science ®Google Scholar
• Bleyer W. A., Haas J. E., Feigl P., et al. Improved Three-Year Disease-Free Survival in Osteogenic Sarcoma. J. Bone Joint Surg. [Br.] 1982; 64: 233–238
   PubMed Web of Science ®Google Scholar
• Rosen G., Marcove R. C., Huvos A. G., et al. Primary Osteogenic Sarcoma: Eight-Year Experience with Adjuvant Chemotherapy. J. Cancer Res. Clin. Oncol. 1983; 106(suppl)55–67
   PubMed Web of Science ®Google Scholar
• Rosen G., Caparros B., Groshen S., et al. Primary Osteogenic Sarcoma of the Femur: A Model for the Use of Preoperative Chemotherapy in High Risk Malignant Tumors. Cancer Invest. 1984; 2: 181–192
   PubMed Web of Science ®Google Scholar
• Pratt C. B., Champion J. E., Fleming I. D., et al. Adjuvant Chemotherapy for Osteosarcoma of the Extremity. Long-Term Results of Two Consecutive Prospective Protocol Studies. Cancer 1990; 65: 439–445
   PubMed Web of Science ®Google Scholar
• Jaffe N., Frei E., Traggis M., et al. Adjuvant Methotrexate and Citrovorum-Factor Treatment of Osteogenic Sarcoma. N. Engl. J. Med. 1974; 29: 994–997
   Web of Science ®Google Scholar
• Goorin A. M., Delorey M., Geller R., et al. The Dana Farber Cancer Institute/The Children’s Hospital Adjuvant Chemotherapy Trials for Osteosarcoma: Three Sequential Studies. Cancer Treat. Symp. 1985; 3: 155–159
   Google Scholar
• Etcubanas E., Wilbut J. R. Adjuvant Chemotherapy for Osteogenic Sarcoma. Cancer Treat. Rep. 1978; 62: 283–287
   PubMedGoogle Scholar
• Jaffe N., Smith E., Abelson H. T., et al. Osteogenic Sarcoma: Alterations in the Pattern of Pulmonary Metastases with Adjuvant Chemotherapy. J. Clin. Oncol. 1983; 1: 251–254
   PubMed Web of Science ®Google Scholar
• Bacci G., Ruggieri P., Picci P., et al. Changing Pattern of Relapse in Osteosarcoma of the Extremities Treated with Adjuvant and Neoadjuvant Chemotherapy. J. Chemother. 1995; 7: 230–239
   PubMed Web of Science ®Google Scholar
• Goorin A. M., Shuster J. J., Baker A., et al. Changing Pattern of Pulmonary Metastases with Adjuvant Chemotherapy in Patients with Osteosarcoma: Results from the Multiinstitutional Osteosarcoma Study. J. Clin. Oncol. 1991; 9: 600–605
   PubMed Web of Science ®Google Scholar
• Edmonson J. H., Green S. J., Ivins J. C., et al. A Controlled Pilot Study of High-Dose Methotrexate as Postsurgical Adjuvant Treatment for Primary Osteosarcoma. J. Clin. Oncol. 1984; 2: 152–156
   PubMed Web of Science ®Google Scholar
• Taylor W. F., Ivins J. C., Dahlin D. C., et al. Trends and Variability in Survival from Osteosarcoma. Mayo Clin. Proc. 1978; 53: 695–700
   PubMed Web of Science ®Google Scholar
• Link M. P., Goorin A. M., Miser A. W., et al. The Effect of Adjuvant Chemotherapy on Relapse-Free Survival in Patients with Osteosarcoma of the Extremity. N. Engl. J. Med. 1986; 314: 1600–1606
   PubMed Web of Science ®Google Scholar
• Eilber F., Giuliano A., Eckardt J., et al. Adjuvant Chemotherapy for Osteosarcoma: A Randomized Prospective Trial. J. Clin. Oncol. 1987; 5: 21–26
   PubMed Web of Science ®Google Scholar
• Bacci G., Gherlinzoni F., Picci P., et al. Adriamycin-Methotrexate High Dose Versus Adriamycin-Methotrexate Moderate Dose as Adjuvant Chemotherapy for Osteosarcoma of the Extremities: A Randomized Study. Eur. J. Cancer Clin. Oncol. 1986; 22: 1337–1345
   PubMedGoogle Scholar
• Briccoli A., Bacci G., Picci P., et al. Changing Pattern of Relapses in Osteosarcoma of the Extremities (OE) Treated with Surgery Alone (SA), or Surgery in Combination with Adjuvant (AC) and Neoadjuvant Chemotherapy (NC). Proc. Am. Soc. Clin. Oncol. 1996; 15: 458, (abstract 1437)
   Google Scholar
• Avella M., Bacci G., McDonald D. J., et al. Adjuvant Chemotherapy with Six Drugs (Adriamycin, Methotrexate, Cisplatinum, Bleomycin, Cyclophosphamide and Dactinomycin) for Non-Metastatic High Grade Osteosarcoma of the Extremities. Results of 32 Patients and Comparison to 127 Patients Concomitantly Treated with the Same Drugs in a Neoadjuvant Form. Chemioterapia 1988; 7: 133–137
   PubMedGoogle Scholar
• Rosen G., Marcove R. C., Caparros B., et al. Primary Osteogenic Sarcoma: The Rationale for Preoperative Chemotherapy and Delayed Surgery. Cancer 1979; 43: 2163–2177
   PubMed Web of Science ®Google Scholar
• Purfurst C., Beron G., Torggler S., et al. Results of the COSS-77 and COSS-80 Studies on Adjuvant Chemotherapy in Osteosarcoma of the Extremities. Klin. Padiatr. 1985; 197: 233–238
   PubMedGoogle Scholar
• Ettinger L. J., Douglass H. O., Jr., Mindell E. R., et al. Adjuvant Adriamycin and Cisplatin in Newly Diagnosed, Nonmetastatic Osteosarcoma of the Extremity. J. Clin. Oncol. 1986; 4: 353–362
   PubMed Web of Science ®Google Scholar
• French Bone Tumor Study Group. Age and Dose of Chemotherapy as Major Prognostic Factors in a Trial of Adjuvant Therapy of Osteosarcoma Combining Two Alternating Drug Combinations and Early Prophylactic Lung Irradiation. Cancer 1988; 61: 1304–1311
   PubMed Web of Science ®Google Scholar
• Maeyama I., Furuse K., Yamawaki S., et al. Evaluation of Adjuvant Chemotherapy of Osteosarcoma with Special Reference to Adriamycin. Gan To Kagaku Ryoho 1988; 15: 3245–3251
   PubMedGoogle Scholar
• Rosen G., Nirenberg A., Caparros B., et al. Osteogenic Sarcoma: Eighty Eight-Percent, Three-Year, Disease-Free Survival with Combination Chemotherapy (T-7). Natl. Cancer Inst. Monogr. 1981; 56: 213–220
   PubMedGoogle Scholar
• Rosen G. Preoperative (Neoadjuvant) Chemotherapy for Osteogenic Sarcoma: A Ten Year Experience. Orthopedics 1985; 8: 659–664
   PubMed Web of Science ®Google Scholar
• Rosen G., Nirenberg A. Neoadjuvant Chemotherapy for Osteogenic Sarcoma: A Five Year Follow-Up (T-10) and Preliminary Report of New Studies (T-12). Prog. Clin. Biol. Res. 1985; 201: 39–51
   PubMedGoogle Scholar
• Rosen G. Preoperative (Neoadjuvant) Chemotherapy for Osteogenic Sarcoma: A Ten Year Experience. Orthopedics 1985; 8: 659–664
   PubMed Web of Science ®Google Scholar
• Fuchs N., Bielack S. S., Epler D., et al. Long-Term Results of the Co-Operative German-Austrian-Swiss Osteosarcoma Study Group’s Protocol COSS-86 of Intensive Multidrug Chemotherapy and Surgery for Osteosarcoma of the Limbs. Ann. Oncol. 1998; 9: 893–899
   PubMed Web of Science ®Google Scholar
• Marsden F. W., Stephens F. O., McCarthy S. W., et al. IIB Osteosarcoma. Current Management, Local Control, and Survival Statistics—the Australian Experience. Clin. Orthop. 1991; 270: 113–119
   PubMedGoogle Scholar
• Saeter G., Alvegard T. A., Elomaa I., et al. Treatment of Osteosarcoma of the Extremities with the T-10 Protocol, with Emphasis on the Effects of Preoperative Chemotherapy with Single-Agent High-Dose Methotrexate: A Scandinavian Sarcoma Group Study. J. Clin. Oncol. 1991; 9: 1766–1775
   PubMed Web of Science ®Google Scholar
• Solheim O. P., Saeter G., Elomaa I., et al. The Treatment of Osteosarcoma: Present Trends. The Scandinavian Sarcoma Group Experience. Ann. Oncol. 1992; 3(suppl 2)S7–S11
   PubMedGoogle Scholar
• Bacci G., Picci P., Ferrari S., et al. Primary Chemotherapy and Delayed Surgery for Nonmetastatic Osteosarcoma of the Extremities. Results in 164 Patients Preoperatively Treated with High Doses of Methotrexate Followed by Cisplatin and Doxorubicin. Cancer 1993; 72: 3227–3238
   PubMed Web of Science ®Google Scholar
• Bacci G., Picci P., Ferrari S., et al. Influence of Adriamycin Dose in the Outcome of Patients with Osteosarcoma Treated with Multidrug Neoadjuvant Chemotherapy: Results of Two Sequential Studies. J. Chemother. 1993; 5: 237–246
   PubMed Web of Science ®Google Scholar
• Jameson M. B., Evans B. D., Gray D. H., et al. Adjuvant Chemotherapy for Non-Metastatic Osteosarcoma of the Extremities in Two New Zealand Cancer Centres. Aust. N.Z. J. Med. 1995; 25: 224–229
   PubMedGoogle Scholar
• Kalifa C., Mlika N., Dubousset J., et al. Experience with Protocol T10 in the Pediatric Service at the Gustave-Roussy Institute. Bull. Cancer 1988; 75: 207–211
   PubMed Web of Science ®Google Scholar
• Miser J., Arndt C., Smithson W., et al. Long Term Follow-Up of High Grade Osteosarcoma (OGS) Treated (TX’D) with Preoperative Ifosfamide (I), Adriamycin (A) and High Dose Methotrexate (M) with Cisplatinum (C) Added Postop for Poor Responders. Proc. Am. Soc. Clin. Oncol. 1998; 17: 535a, (abstract 2054)
   Google Scholar
• Uchida A., Myoui A., Araki N., et al. Neoadjuvant Chemotherapy for Pediatric Osteosarcoma Patients. Cancer 1997; 79: 411–415
   PubMed Web of Science ®Google Scholar
• Meyers P. A., Gorlick R., Heller G., et al. Intensification of Preoperative Chemotherapy for Osteogenic Sarcoma: Results of the Memorial Sloan-Kettering (T12) Protocol. J. Clin. Oncol. 1998; 16: 2452–2458
   PubMed Web of Science ®Google Scholar
• Winkler K., Beron G., Kotz R., et al. Adjuvant Chemotherapy in Osteosarcoma—Effects of Cisplatinum, BCD, and Fibroblast Interferon in Sequential Combination with HD-MTX and Adriamycin. Preliminary Results of the COSS 80 Study. J. Cancer Res. Clin. Oncol. 1983; 106(suppl)1–7
   PubMedGoogle Scholar
• Winkler K., Beron G., Kotz R., et al. Neoadjuvant Chemotherapy for Osteogenic Sarcoma: Results of a Cooperative German/Austrian study. J. Clin. Oncol. 1984; 2: 617–624
   PubMed Web of Science ®Google Scholar
• Winkler K., Beron G., Delling G., et al. Neoadjuvant Chemotherapy of Osteosarcoma: Results of a Randomized Cooperative Trial (COSS-82) with Salvage Chemotherapy Based on Histological Tumor Response. J. Clin. Oncol. 1988; 6: 329–337
   PubMed Web of Science ®Google Scholar
• Bacci G., Picci P., Ruggieri P., et al. Primary Chemotherapy and Delayed Surgery (Neoadjuvant Chemotherapy) for Osteosarcoma of the Extremities. The Istituto Rizzoli Experience in 127 Patients Treated Preoperatively with Intravenous Methotrexate (High Versus Moderate Doses) and Intraarterial Cisplatin. Cancer 1990; 65: 2539–2553
   PubMed Web of Science ®Google Scholar
• Bacci G., Picci P., Gherlinzoni F., et al. Neoadjuvant Chemotherapy for High Grade Osteosarcoma of the Extremities: Is a Good Response to Preoperative Treatment an Indication to Reduce Postoperative Chemotherapyquest;. Chemioterapia 1986; 5: 140–143
   PubMedGoogle Scholar
• Bramwell V. H., Burgers M., Sneath R., et al. A Comparison of Two Short Intensive Adjuvant Chemotherapy Regimens in Operable Osteosarcoma of Limbs in Children and Young Adults: The First Study of the European Osteosarcoma Intergroup. J. Clin. Oncol. 1992; 10: 1579–1591
   PubMed Web of Science ®Google Scholar
• Souhami R. L., Craft A. W., Van der Eijken J. W., et al. Randomized Trial of Two Regimens of Chemotherapy in Operable Osteosarcoma: A Study of the European Osteosarcoma Intergroup. Lancet 1997; 350: 911–917
   PubMed Web of Science ®Google Scholar
• Goorin A., Baker A., Gieser P., et al. No Evidence for Improved Event Free Survival (EFS) with Pre-surgical Chemotherapy (PRE) for Non-Metastatic Extremity Osteogenic Sarcoma (OGS): Preliminary Results of Randomized Pediatric Oncology Group (POG) Trial 8651. Proc. Am. Soc. Clin. Oncol. 1995; 15: 444, (abstract 1420)
   Google Scholar
• Marti C., Kroner T., Remagen W., et al. High-Dose Ifosfamide in Advanced Osteosarcoma. Cancer Treat. Rep. 1985; 69: 115–117
   PubMedGoogle Scholar
• Bieling P., Bielack S., Delling G., et al. Neoadjuvant Chemotherapy of Osteosarcoma. Preliminary Results of the Cooperative COSS-86 Osteosarcoma Study. Klin. Padiatr. 1991; 203: 220–230
   PubMed Web of Science ®Google Scholar
• Harris M. B., Cantor A. B., Goorin A. M., et al. Treatment of Osteosarcoma with Ifosfamide: Comparison of Response in Pediatric Patients with Recurrent Disease Versus Patients Previously Untreated: A Pediatric Oncology Group Study. Med. Pediatr. Oncol. 1995; 24: 87–92
   PubMedGoogle Scholar
• Harris M., Gieser P., Link M., et al. Treatment of Metastatic Osteosarcoma at Diagnosis. A Pediatric Oncology Group Study. Proc. Am. Soc. Clin. Oncol. 1995; 14: 445, (abstract 1422)
   Google Scholar
• Harris M. B., Gieser P., Goorin A. M., et al. Treatment of Metastatic Osteosarcoma at Diagnosis: A Pediatric Oncology Group Study. J. Clin. Oncol. 1998; 16: 3641–3648
   PubMed Web of Science ®Google Scholar
• Bacci G., Picci P., Pignatti G., et al. Neoadjuvant Chemotherapy for Nonmetastatic Osteosarcoma of the Extremities. Clin. Orthop. 1991; 270: 87–98
   PubMedGoogle Scholar
• Epelman S., Seibel N., Melaragno R., et al. Treatment of Newly Diagnosed High Grade Osteosarcoma (OS) with Ifosfamide (IFOS), Adriamycin (ADR), and Cisplatin (CDP) Without High Dose Methotrexate. Proc. Am. Soc. Clin. Oncol. 1995; 14: 439, (abstract 1399)
   Google Scholar
• Gentet J. C., Brunat-Mentigny M., Kalifa C., et al. Ifosfamide (IFO) and Etoposide (VP) in Refractory or Recurrent Childhood Osteosarcoma (OS). A Phase II Study of the French Society of Pediatric Oncology (SFOP). Proc. Am. Soc. Clin. Oncol. 1995; 14: 450, (abstract 1443)
   Google Scholar
• Delord J. P., Fizazi K., Cojean-Zelek I. High-Dose (HD) Ifosfamide and Etoposide +G-CSF in Pretreated Adults with Ewing’s Sarcoma and Osteosarcoma. Proc. Am. Soc. Clin. Oncol. 1998; 17: 520a, (abstract 2000)
   Google Scholar
• Goorin A. M., Gieser P., Ferguson W., et al. Successful Phase II Trial of Etoposide and High Dose Ifosfamide in Newly Diagnosed Metastatic Osteosarcoma: A Pediatric Oncology Group Trial (POG). Proc. Am. Soc. Clin. Oncol. 1998; 17: 535s, (abstract 2056)
   Google Scholar
• Gentet J. C., Brunat-Mentigny M., Demaille M. C., et al. Ifosfamide and Etoposide in Childhood Osteosarcoma. A Phase II Study of the French Society of Paediatric Oncology. Eur. J. Cancer 1997; 33: 232–237
   PubMed Web of Science ®Google Scholar
• Bacci G., Picci P., Ferrari S., et al. Neoadjuvant Chemotherapy for the Treatment of Osteosarcoma of the Extremities: Excellent Response of the Primary Tumor to Preoperative Treatment with Methotrexate, Cisplatin, Adriamycin, and Ifosfamide. Preliminary Results. Chir. Organi. Mov. 1995; 80: 1–10
   PubMedGoogle Scholar
• Bacci G., Ferrari S., Forni C., et al. The Effect of Intra-Arterial Versus Intravenous Cisplatinum in the Neoadjuvant Treatment of Osteosarcoma of the Limbs: The Experience at the Rizzoli Institute. Chir. Organi. Mov. 1996; 81: 369–382
   PubMedGoogle Scholar
• Munoz A. Villa, Ocete G., Aymerich M. L., et al. Preoperative and Postoperative Chemotherapy of Osteogenic Sarcoma of the Limbs in Children. Med. Clin. (Barc.) 1996; 107: 161–164
   PubMed Web of Science ®Google Scholar
• Pratt C. B., Epelman S., Jaffe N. Bleomycin, Cyclophosphamide, and Dactinomycin in Metastatic Osteosarcoma: Lack of Tumor Regression in Previously Treated Patients. Cancer Treat. Rep. 1987; 71: 421–423
   PubMedGoogle Scholar
• Scharstein R., Johnson J. F., Cook B. A., et al. Bleomycin Nodules Mimicking Metastatic Osteogenic Sarcoma. Am. J. Pediatr. Hematol. Oncol. 1987; 9: 219–221
   PubMedGoogle Scholar
• Santrach P. J., Askin F. B., Wells R. J., et al. Nodular Form of Bleomycin-Related Pulmonary Injury in Patients with Osteogenic Sarcoma. Cancer 1989; 64: 806–811
   PubMed Web of Science ®Google Scholar
• Kharasch V. S., Lipsitz S., Santis W., et al. Long-Term Pulmonary Toxicity of Multiagent Chemotherapy Including Bleomycin and Cyclophosphamide in Osteosarcoma Survivors. Med. Pediatr. Oncol. 1996; 27: 85–91
   PubMedGoogle Scholar
• Saleh R. A., Graham-Pole J., Cassano W., et al. Response of Osteogenic Sarcoma to the Combination of Etoposide and Cyclophosphamide as Neoadjuvant Chemotherapy. Cancer 1990; 65: 861–865
   PubMed Web of Science ®Google Scholar
• Cairo M. S. The Use of Ifosfamide, Carboplatin, and Etoposide in Children with Solid Tumors. Semin. Oncol. 1995; 22(3 suppl 7)23–27
   PubMed Web of Science ®Google Scholar
• Kung F. H., Desai S. J., Dickerman J. D., et al. Ifosfamide/Carboplatin/Etoposide (ICE) for Recurrent Malignant Solid Tumors of Childhood: A Pediatric Oncology Group Phase I/II Study. J. Pediatr. Hematol. Oncol. 1995; 17: 265–269
   PubMed Web of Science ®Google Scholar
• Hirota T., Takeuchi M., Iwata A., et al. Pilot Study of Relapsed Osteosarcoma and Brain Tumor with Ifosfamide, Carboplatin and Etoposide. Gan To Kagaku Ryoho 1998; 25: 385–390
   PubMedGoogle Scholar
• Ferguson W., Harris M., Link M., et al. Carboplatin in the Treatment of Newly-Diagnosed Metastatic or Unresectable Osteosarcoma: A Pediatric Oncology Group Study. Proc. Am. Soc. Clin. Oncol. 1996; 15: 521, (abstract 1678)
   Google Scholar
• Ferguson W. S., Harris M. B., Goorin A. M., et al. Carboplatin Followed by Surgery and Multi-Drug Chemotherapy for the Treatment of Newly-Diagnosed Metastatic or Unresectable Osteosarcoma: A Pediatric Oncology Group Phase II/III Trial, in press
   Google Scholar
• Pratt C. B., Harper J., Fletcher B., et al. Ifosfamide (IFOS) and Carboplatin (CARBO) Window Therapy in Previously Untreated Osteosarcoma (OS). Proc. Am. Soc. Clin. Oncol. 1995; 14(1410)442
   Google Scholar
• Meyer W. H., Pratt C. B., Rao B. N., et al. Curative Therapy for Osteosarcoma Without Cisplatin—Preliminary Results of SJCRH OS-91. Proc. Am. Soc. Clin. Oncol. 1997; 16: 512a, (abstract 1842)
   Google Scholar
• Jaffe N., Knapp J., Chuang V. P., et al. Osteosarcoma: Intra-arterial Treatment of the Primary Tumor with Cis-Diammine-Dichloroplatinum II (CDP). Angiographic, Pathologic, and Pharmacologic Studies. Cancer 1983; 51: 402–407
   PubMed Web of Science ®Google Scholar
• Bacci G., Avella M., Brach Del Prevert A., et al. Neoadjuvant Chemotherapy for Osteosarcoma of the Extremities. Good Response of the Primary Tumor After Preoperative Chemotherapy with High-Dose Methotrexate Followed by Cisplatinum and Adriamycin. Preliminary Results. Chemioterapia 1988; 7: 138–142
   PubMedGoogle Scholar
• Stine K. C., Hockenberry M. J., Harrelson J., et al. Systemic Doxorubicin and Intraarterial Cisplatin Preoperative Chemotherapy Plus Postoperative Adjuvant Chemotherapy in Patients with Osteosarcoma. Cancer 1989; 63: 848–853
   PubMed Web of Science ®Google Scholar
• Kashdan B. J., Sullivan K. L., Lackman R. D., et al. Extremity Osteosarcomas: Intraarterial Chemotherapy and Limb-Sparing Resection with 2-Year Follow-Up. Radiology 1990; 177: 95–99
   PubMed Web of Science ®Google Scholar
• Bacci G., Picci P., Ruggieri P., et al. Neoadjuvant Chemotherapy for the Treatment of Osteosarcoma of the Limbs. Preliminary Results in 100 Patients Treated Preoperatively with High Doses of Methotrexate I.V. Followed by Cisplatin (i.a.) and Adriamycin. Chir. Organi. Mov. 1991; 76: 1–16
   PubMedGoogle Scholar
• Bacci G., Picci P., Avella M., et al. Effect of Intra-Arterial Versus Intravenous Cisplatin in Addition to Systemic Adriamycin and High-Dose Methotrexate on Histologic Tumor Response of Osteosarcoma of the Extremities. J. Chemother. 1992; 4: 189–195
   PubMed Web of Science ®Google Scholar
• Bacci G., Ruggieri P., Picci P., et al. Intra-Arterial Versus Intravenous Cisplatinum (in Addition to Systemic Adriamycin and High Dose Methotrexate) in the Neoadjuvant Treatment of Osteosarcoma of the Extremities. Results of a Randomized Study. J. Chemother. 1996; 8: 70–81
   PubMed Web of Science ®Google Scholar
• Lackman R. D., Weiss A. Long Term Results of Intra-Arterial Pre-Operative Chemotherapy for Osteosarcoma. Proc. Am. Soc. Clin. Oncol. 1996; 15: 526, (abstract 1697)
   Google Scholar
• Winkler K., Bielack S., Delling G., et al. Effect of Intraarterial Versus Intravenous Cisplatin in Addition to Systemic Doxorubicin, High-Dose Methotrexate, and Ifosfamide on Histologic Tumor Response in Osteosarcoma (Study COSS-86). Cancer 1990; 66: 1703–1710
   PubMed Web of Science ®Google Scholar
• Jaffe N. Pediatric Osteosarcoma: Treatment of the Primary Tumor with Intraarterial Cis-Diamminedichloroplatinum-II (CDP)—Advantages, Disadvantages, and Controversial Issues. Cancer Treat. Res. 1993; 62: 75–84
   PubMedGoogle Scholar
• Bielack S. S., Bieling P., Erttmann R., et al. Intraarterial Chemotherapy for Osteosarcoma: Does the Result Really Justify the Effort?. Cancer Treat. Res. 1993; 62: 85–92
   PubMedGoogle Scholar
• Jaffe N., Prudich J., Knapp J., et al. Treatment of Primary Osteosarcoma with Intra-Arterial and Intravenous High-Dose Methotrexate. J. Clin. Oncol. 1983; 1: 428–431
   PubMed Web of Science ®Google Scholar
• Malawer M., Buch R., Reaman G., et al. Impact of Two Cycles of Preoperative Chemotherapy with Intraarterial Cisplatin and Intravenous Doxorubicin on the Choice of Surgical Procedure for High-Grade Bone Sarcomas of the Extremities. Clin. Orthop. 1992; 270: 214–222
   Google Scholar
• Bacci G., Springfield D., Capanna R., et al. Neoadjuvant Chemotherapy for Osteosarcoma of the Extremity. Clin. Orthop. 1987; 224: 268–276
   PubMedGoogle Scholar
• Winkler K., Bieling P., Bielack S. Chemotherapy of Osteosarcoma. Z. Orthop. Ihre Grenzgeb. 1992; 130: 285–289
   PubMed Web of Science ®Google Scholar
• Picci P., Sangiorgi L., Rougraff B. T., et al. Relationship of Chemotherapy-Induced Necrosis and Surgical Margins to Local Recurrence in Osteosarcoma. J. Clin. Oncol. 1994; 12: 2699–2705
   PubMed Web of Science ®Google Scholar
• Juergens H., Kosloff C., Nirenberg A., et al. Prognostic Factors in the Response of Primary Osteogenic Sarcoma to Preoperative Chemotherapy (High-Dose Methotrexate with Citrovorum Factor). Natl. Cancer Inst. Monogr. 1981; 56: 221–226
   PubMedGoogle Scholar
• Honegger H. P., Cserhati M. D., Exner G. U., et al. Zurich Experience with Preoperative, High Dose Methotrexate-Containing Chemotherapy in Patients with Extremity Osteosarcomas (OSA). Ann. Oncol. 1991; 2: 489–494
   PubMed Web of Science ®Google Scholar
• Winkler K., Bieling P., Bielack S., et al. Local Control and Survival from the Cooperative Osteosarcoma Study Group Studies of the German Society of Pediatric Oncology and the Vienna Bone Tumor Registry. Clin. Orthop. 1991; 270: 79–86
   PubMed Web of Science ®Google Scholar
• Benjamin R. S., Chawla S. P., Carrasco C. H., et al. Preoperative Chemotherapy for Osteosarcoma with Intravenous Adriamycin and Intra-Arterial Cis-Platinum. Ann. Oncol. 1992; 3(suppl 2)S3–2
   PubMed Web of Science ®Google Scholar
• Nachman J., Simon M. A., Dean L., et al. Disparate Histologic Responses in Simultaneously Resected Primary and Metastatic Osteosarcoma Following Intravenous Neoadjuvant Chemotherapy. J. Clin. Oncol. 1987; 5: 1185–1190
   PubMed Web of Science ®Google Scholar
• Bacci G., Picci P., Ferrari S., et al. Synchronous Multifocal Osteosarcoma: Results in Twelve Patients Treated with Neoadjuvant Chemotherapy and Simultaneous Resection of All Involved Bones. Ann. Oncol. 1996; 7: 864–866
   PubMed Web of Science ®Google Scholar
• Rosen G., Caparros B., Huvos A. G., et al. Preoperative Chemotherapy for Osteogenic Sarcoma: Selection of Postoperative Adjuvant Chemotherapy Based on the Response of the Primary Tumor to Preoperative Chemotherapy. Cancer 1982; 49: 1221–1230
   PubMed Web of Science ®Google Scholar
• Winkler K., Bielack S. S., Delling F., et al. Treatment of Osteosarcoma. Experience of the Cooperative Osteosarcoma Study Group (COSS). Cancer Treat. Res. 1993; 62: 269–277
   PubMedGoogle Scholar
• Kumpan W., Lechner G., Wittich G. R., et al. The Angiographic Response of Osteosarcoma Following PreOperative Chemotherapy. Skeletal Radiol 1986; 15: 96–102
   PubMed Web of Science ®Google Scholar
• Holscher H. C., Hermans J., Nooy M. A., et al. Can Conventional Radiographs Be Used to Monitor the Effect of Neoadjuvant Chemotherapy in Patients with Osteogenic Sarcoma?. Skeletal Radiol. 1996; 25: 19–24
   PubMed Web of Science ®Google Scholar
• Wellings R. M., Davies A. M., Pynsent P. B., et al. The Value of Computed Tomographic Measurements in Osteosarcoma as a Predictor of Response to Adjuvant Chemotherapy. Clin. Radiol. 1994; 49: 19–23
   PubMed Web of Science ®Google Scholar
• Holscher H. C., Bloem J. L., Vanel D., et al. Osteosarcoma: Chemotherapy-Induced Changes at MR Imaging. Radiology 1992; 182: 839–844
   PubMed Web of Science ®Google Scholar
• Menendez L. R., Fideler B. M., Mirra J. Thallium-201 Scanning for the Evaluation of Osteosarcoma and Soft-Tissue Sarcoma. A Study of the Evaluation and Predictability of the Histological Response to Chemotherapy. J. Bone Joint Surg. Am. 1993; 75: 526–531
   PubMed Web of Science ®Google Scholar
• Lin J., Leung W. T., Ho S. K., et al. Quantitative Evaluation of Thallium-201 Uptake in Predicting Chemotherapeutic Response of Osteosarcoma. Eur. J. Nucl. Med. 1995; 22: 553–555
   PubMedGoogle Scholar
• Ohtomo K., Terui S., Yokoyama R., et al. Thallium-201 Scintigraphy to Assess Effect of Chemotherapy in Osteosarcoma. J. Nucl. Med. 1996; 37: 1444–1448
   PubMed Web of Science ®Google Scholar
• Imbriaco M., Yeh S. D., Yeung H., et al. Thallium-201 Scintigraphy for the Evaluation of Tumor Response to Preoperative Chemotherapy in Patients with Osteosarcoma. Cancer 1997; 80: 1507–1512
   PubMed Web of Science ®Google Scholar
• Hori A., Sumiya H., Taki J., et al. Thallium-201 SPECT in Differentiating Bone Infarction from Metastatic Lesions in Osteosarcoma. Clin. Nucl. Med. 1997; 22: 752–755
   PubMed Web of Science ®Google Scholar
• Edeline V., Frouin F., Bazin J. P., et al. Factor Analysis as a Means of Determining Response to Chemotherapy in Patients with Osteogenic Sarcoma. Eur. J. Nucl. Med. 1993; 20: 1175–1185
   PubMedGoogle Scholar
• Soderlund V., Larsson S. A., Bauer H. C.F., et al. Use of 99mTc-MIBI Scintigraphy in the Evaluation of the Response of Osteosarcoma to Chemotherapy. Eur. J. Nucl. Med. 1997; 24: 511–515
   PubMedGoogle Scholar
• Lang P., Vahlensieck M., Matthay K. K., et al. Monitoring Neovascularity as an Indicator to Response to Chemotherapy in Osteogenic and Ewing’s Sarcoma Using Magnetic Resonance Angiography. Med. Pediatr. Oncol. 1996; 26: 329–333
   PubMedGoogle Scholar
• Bonnerot V., Charpentier A., Frouin F., et al. Factor Analysis of Dynamic Magnetic Resonance Imaging in Predicting the Response of Osteosarcoma to Chemotherapy. Invest. Radiol. 1992; 27: 847–855
   PubMed Web of Science ®Google Scholar
• Van der Woude H. J., Bloem J. L., Verstraete K. L., et al. Osteosarcoma and Ewing’s Sarcoma After Neoadjuvant Chemotherapy: Value of Dynamic MR Imaging in Detecting Viable Tumor Before Surgery. Am. J. Roentgenol. 1995; 165: 593–598
   PubMed Web of Science ®Google Scholar
• Reddick W. E., Bhargava R., Taylor J. S., et al. Dynamic Contrast-Enhanced MR Imaging Evaluation of Osteosarcoma Response to Neoadjuvant Chemotherapy. J. Magn. Reson. Imaging 1995; 5: 689–694
   PubMed Web of Science ®Google Scholar
• De Baere T., Vanel D., Shapeero L. G., et al. Osteosarcoma After Chemotherapy: Evaluation with Contrast Material-Enhanced Subtraction MR Imaging. Radiology 1992; 85: 587–592
   Google Scholar
• Van der Woude H. J., Bloem J. L., van Oostayen J. A., et al. Treatment of High-Grade Bone Sarcomas with Neoadjuvant Chemotherapy: The Utility of Sequential Color Doppler Sonography in Predicting Histopathologic Response. Am. J. Roentgenol. 1995; 165: 125–133
   PubMed Web of Science ®Google Scholar
• Carrasco C. H., Charnsangavej C., Raymond A. K., et al. Osteosarcoma: Angiographic Assessment of Response to Preoperative Chemotherapy. Radiology 1989; 170(3 pt 1)839–842
   PubMed Web of Science ®Google Scholar
• Abella E., DiCarli M., Ravindranath Y., et al. Positron Emission Tomography (PET) Scanning with 18Flurodeoxyglucose [FDG] Correlates with Histologic Response in Children with Osteosarcoma [OS] and Ewing Sarcoma [ES]. Proc. Am. Soc. Clin. Oncol. 1996; 15: 463, (abstract 1457)
   Google Scholar
• Baldini N., Scotlandi K., Barbanti-Brodano G., et al. Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome. N. Engl. J. Med. 1995; 333: 1380–1385
   PubMed Web of Science ®Google Scholar
• Serra M., Scotlandi K., Manara M. C., et al. Analysis of P-Glycoprotein Expression in Osteosarcoma. Eur. J. Cancer 1995; 31A: 1998–2002
   PubMed Web of Science ®Google Scholar
• Scotlandi K., Serra M., Nicolett G., et al. Multidrug Resistance and Malignancy in Human Osteosarcoma. Cancer Res. 1996; 56: 2434–2439
   PubMed Web of Science ®Google Scholar
• Chan H. S., Grogan T. M., Haddad G., et al. P-Glycoprotein Expression: Critical Determinant in the Response to Osteosarcoma Chemotherapy. J. Natl. Cancer Inst. 1997; 89: 1706–1715
   PubMed Web of Science ®Google Scholar
• Takeshita H., Gebhardt M. C., Springfield D. S., et al. Experimental Models for the Study of Drug Resistance in Osteosarcoma: P-Glycoprotein-Positive, Murine Osteosarcoma Cell Lines. J. Bone Joint Surg. Am. 1996; 78: 366–375
   PubMedGoogle Scholar
• Brach Del Prever A., Massara F. M., Besenzon L., et al. Treatment of Metastatic Osteosarcoma with Verapamil, Cyclosporine and Chemotherapy. A Case Report. Minerva Pediatr. 1995; 47: 147–151
   PubMedGoogle Scholar
• Goorin A. M., Andersen J. W. Experience with Multiagent Chemotherapy for Osteosarcoma. Improved Outcome. Clin. Orthop. 1991; 270: 22–28
   PubMed Web of Science ®Google Scholar
• Bacci G., Picci P., Avella M., et al. The Importance of Dose-Intensity in Neoadjuvant Chemotherapy of Osteosarcoma: A Retrospective Analysis of High-Dose Methotrexate, Cisplatinum and Adriamycin Used Preoperatively. J. Chemother. 1990; 2: 127–135
   PubMed Web of Science ®Google Scholar
• Ogihara Y., Sudo A., Fujinami S., et al. Current Management, Local Management, and Survival Statistics of High-Grade Osteosarcoma. Experience in Japan. Clin. Orthop. 1991; 270: 72–78
   PubMedGoogle Scholar
• Wagener D. J., van Oosterom A. T., Mulder J. H., et al. Phase II Study of Low-Dose Methotrexate in Advanced Osteosarcoma Followed by Escalation After Disease Progression: A Study of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research on Treatment of Cancer. Cancer Treat. Rep. 1986; 70: 615–618
   PubMedGoogle Scholar
• Ferrari S., Sassoli V., Orlandi M., et al. Serum Methotrexate (MTX) Concentrations and Prognosis in Patients with Osteosarcoma of the Extremities Treated with a Multidrug Neoadjuvant Regimen. J. Chemother. 1993; 5: 135–141
   PubMed Web of Science ®Google Scholar
• Takahashi M., Katagiri H., Sato K., et al. The Importance of Dose Intensity in Preoperative Chemotherapy for Osteosarcoma—Retrospective Analysis of a Short Intensive Chemotherapy Regimen Preoperatively Using High-Dose Methotrexate and Cisplatinum. Gan To Kagaku Ryoho 1994; 21: 459–464
   PubMedGoogle Scholar
• Delepine N., Delepine G., Cornille H., et al. Dose Escalation with Pharmacokinetics Monitoring in Methotrexate Chemotherapy of Osteosarcoma. Anticancer Res. 1995; 15: 489–494
   PubMed Web of Science ®Google Scholar
• Kawai A., Sugihara S., Kunisada T., et al. The Importance of Doxorubicin and Methotrexate Dose Intensity in the Chemotherapy of Osteosarcoma. Arch. Orthop. Trauma Surg. 1996; 115: 68–70
   PubMed Web of Science ®Google Scholar
• Delepine N., Delepine G., Bacci G., et al. Influence of Methotrexate Dose Intensity on Outcome of Patients with High Grade Osteogenic Osteosarcoma. Analysis of the Literature. Cancer 1996; 78: 2127–2135
   PubMed Web of Science ®Google Scholar
• Bacci G., Ferrari S., Picci P., et al. Methotrexate Serum Concentration and Histologic Response to Multiagent Primary Chemotherapy for Osteosarcoma of the Limbs. J. Chemother. 1996; 8: 472–478
   PubMed Web of Science ®Google Scholar
• Smith M. A., Ungerleider R. S., Horowitz M. E., et al. Influence of Doxorubicin Dose Intensity on Response and Outcome for Patients with Osteogenic Sarcoma and Ewing’s Sarcoma. J. Natl. Cancer Inst. 1991; 83: 1460–1470
   PubMed Web of Science ®Google Scholar
• Smith M., Simon R., Cain D., et al. Children and Cancer. A Perspective from the Cancer Therapy Evaluation Program, National Cancer Institute. Cancer 1993; 71(10 suppl)3422–3428
   PubMed Web of Science ®Google Scholar
• Delepine G., Delepine N. Prognostic Value of Dose Intensity of Drugs in Localized Osteosarcoma Treated by Protocols Excluding High-Dose Methotrexate. A Literature Analysis. Proc. Am. Soc. Clin. Oncol. 1997; 16: 504a, (abstract 1811)
   Google Scholar
• Leung S., Marshall G. M., Mahr M. al, et al. Prognostic Significance of Chemotherapy Dosage Characteristics in Children with Osteogenic Sarcoma. Med. Pediatr. Oncol. 1997; 28: 179–182
   PubMedGoogle Scholar
• Goorin A. M., Cantor A., Link M. P. A Phase I Trial of Etoposide (VP) and Escalating Doses of Ifosfamide (IFOS) Plus G-CSF in Recurrent Pediatric Sarcomas. Proc. Am. Soc. Clin. Oncol. 1994; 13: 425, (abstract 1458)
   Google Scholar
• Picci P., Bacci G., Ferrari S., et al. Salvage Treatment with High-Dose Ifosfamide and Surgery for Osteosarcoma Patients Relapsed with Lung Metastases. Preliminary Results. Proc. Am. Soc. Clin. Oncol. 1996; 15: 459, (abstract 1438)
   Google Scholar
• Brain E. C., Mita A., Soulie P., et al. 6-Day Continuous Infusion of High-Dose Ifosfamide with Bone Marrow Growth Factors in Advanced Refractory Malignancies. J. Cancer Res. Clin. Oncol. 1997; 123: 227–231
   PubMed Web of Science ®Google Scholar
• Souhami R. L., Nooy M., van der Eijken J., et al. A Randomized Trial of Two Regimens of Chemotherapy in Operable Osteosarcoma: A Study of the European Osteosarcoma Intergroup (EOI). Proc. Am. Soc. Clin. Oncol. 1996; 15: 520, (abstract 1676)
   Google Scholar
• Wada T., Isu K., Takeda N., et al. A Preliminary Report of Neoadjuvant Chemotherapy NSH-7 Study in Osteosarcoma: Preoperative Salvage Chemotherapy Based on Clinical Tumor Response and the Use of Granulocyte Colony-Stimulating Factor. Oncology 1996; 53: 221–227
   PubMed Web of Science ®Google Scholar
• Tsuchiya H., Yasutake H., Yokogawa A., et al. Effect of Chemotherapy Combined with Caffeine for Osteosarcoma. J. Cancer Res. Clin. Oncol. 1992; 118: 567–569
   PubMed Web of Science ®Google Scholar
• Tsuchiya H., Tomita K., Mori Y., et al. Caffeine-Assisted Chemotherapy and Minimized Tumor Excision for Nonmetastatic Osteosarcoma. Anticancer Res. 1998; 18(1B)657–666
   PubMed Web of Science ®Google Scholar
• Rosenburg S. A., Chabner B. A., Young R. C., et al. Treatment of Osteogenic Sarcoma. I. Effect of Adjuvant High-Dose Methotrexate After Amputation. Cancer Treat. Rep. 1979; 63: 739–751
   PubMedGoogle Scholar
• Gilchrist G. S., Ivins J. C., Ritts R. E., Jr., et al. Adjuvant Therapy for Nonmetastatic Osteogenic Sarcoma: An Evaluation of Transfer Factor Versus Combination Chemotherapy. Cancer Treat. Rep. 1978; 62: 289–294
   PubMedGoogle Scholar
• Kleinerman E. S., Jia S. F., Griffin J., et al. Phase II Study of Liposomal Muramyl Tripeptide in Osteosarcoma: The Cytokine Cascade and Monocyte Activation Following Administration. J. Clin. Oncol. 1992; 10: 1310–1316
   PubMed Web of Science ®Google Scholar
• Kleinerman E. S., Snyder J. S., Jaffe N. Influence of Chemotherapy Administration on Monocyte Activation by Liposomal Muramyl Tripeptide Phosphatidylethanolamine in Children with Osteosarcoma. J. Clin. Oncol. 1991; 9: 259–267
   PubMed Web of Science ®Google Scholar
• Kleinerman E. S., Raymond A. K., Bucana C. D., et al. Unique Histologic Changes in Lung Metastases of Osteosarcoma Patients Following Therapy with Liposomal Muramyl Tripeptide (CGP 19835A Lipid). Cancer Immunol. Immunother. 1992; 34: 211–220
   PubMed Web of Science ®Google Scholar
• Kleinerman E. S., Maeda M., Jaffe N. Liposome-Encapsulated Muramyl Tripeptide: A New Biologic Response Modifier for the Treatment of Osteosarcoma. Cancer Treat. Res. 1993; 62: 101–107
   PubMedGoogle Scholar
• Asano T., Kleinerman E. S. Liposome-Encapsulated MTP-PE: A Novel Biologic Agent for Cancer Therapy. J. Immunother. 1993; 14: 286–292
   PubMed Web of Science ®Google Scholar
• Kleinerman E. S., Meyers P. A., Raymond A. K., et al. Combination Therapy with Ifosfamide and Liposome-Encapsulated Muramyl Tripeptide: Tolerability, Toxicity, and Immune Stimulation. J. Immunother. Emphasis Tumor Immunol. 1995; 17: 181–193
   PubMed Web of Science ®Google Scholar
• Kleinerman E. S., Gano J. B., Johnston D. A., et al. Efficacy of Liposomal Muramyl Tripeptide (CGP 19835A) in the Treatment of Relapsed Osteosarcoma. Am. J. Clin. Oncol. 1995; 18: 93–99
   PubMed Web of Science ®Google Scholar
• Ko S. C., Cheon J., Kao C., et al. Osteocalcin Promoter-Based Toxic Gene Therapy for the Treatment of Osteosarcoma in Experimental Models. Cancer Res. 1996; 56: 4614–4619
   PubMed Web of Science ®Google Scholar
• Degreve B., Andrei G., Izquierdo M., et al. Varicella-Zoster Virus Thymidine Kinase Gene and Antiherpetic Pyrimidine Nucleoside Analogues in a Combined Gene/Chemotherapy Treatment for Cancer. Gene Ther. 1997; 4: 1107–1114
   PubMed Web of Science ®Google Scholar
• Cheon J., Ko S. C., Gardner T. A., et al. Chemogene Therapy: Osteocalcin Promoter-Based Suicide Gene Therapy in Combination with Methotrexate in a Murine Osteosarcoma Model. Cancer Gene Ther. 1997; 4: 359–365
   PubMed Web of Science ®Google Scholar
• Chen D. S., Zhu N. L., Hung G., et al. Retroviral Vector-Mediated Transfer of an Antisense Cyclin G1 Construct Inhibits Osteosarcoma Tumor Growth in Nude Mice. Hum. Gene Ther. 1997; 8: 1667–1674
   PubMed Web of Science ®Google Scholar
• Pinski J., Schally A. V., Halmos G., et al. Somatostatin Analog RC-160 Inhibits the Growth of Human Osteosarcomas in Nude Mice. Int. J. Cancer 1996; 65: 870–874
   PubMed Web of Science ®Google Scholar
• Pinski J., Schally A. V., Groot K., et al. Inhibition of Growth of Human Osteosarcomas by Antagonists of Growth Hormone-Releasing Hormone. J. Natl. Cancer Inst. 1995; 87: 1787–1794
   PubMed Web of Science ®Google Scholar
• Morishita T., Mii Y., Miyauchi Y., et al. Efficacy of the Angiogenesis Inhibitor O-(Chloroacetyl-Carbamoyl)Fumagillol (AGM-1470) on Osteosarcoma Growth and Lung Metastasis in Rats. Jpn. J. Clin. Oncol. 1995; 25: 25–31
   PubMed Web of Science ®Google Scholar
• Hosain F., Spencer R. P., Couthon H. M., et al. Targeted Delivery of Antineoplastic Agent to Bone: Biodistribution Studies of Technetium-99m-Labeled Gem-Bisphosphonate Conjugate of Methotrexate. J. Nucl. Med. 1996; 37: 105–107
   PubMed Web of Science ®Google Scholar
• Hayakawa M., Kawaguchi S., Ishii S., et al. B7-1-Transfected Tumor Vaccine Counteracts Chemotherapy-Induced Immunosuppression and Prolongs the Survival of Rats Bearing Highly Metastatic Osteosarcoma Cells. Int. J. Cancer 1997; 71: 1091–1102
   PubMed Web of Science ®Google Scholar
• Navid F., Yeung C. L., Sangiorgi L., et al. Autocrine Activity of TGFβ in Murine Osteosarcoma Cell Lines. Proc. Am. Soc. Clin. Oncol. 1997; 16: 527a, (abstract 1900)
   Google Scholar
• Baselga J., Tripathy D., Mendelsohn J., et al. Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185HER2 Monoclonal Antibody in Patients with HER2/neu-Overexpessing Metastatic Breast Cancer. J. Clin. Oncol 1996; 14: 737–744
   PubMed Web of Science ®Google Scholar
• Simon M. A., Aschliman M. A., Thomas N, et al. Limb-Salvage Treatment Versus Amputation for Osteosarcoma of the Distal End of the Femur. J. Bone Joint Surg [Am.] 1986; 68: 1331–1337
   PubMed Web of Science ®Google Scholar
• Kempf-Bielack B, Bielack S, Bieling P, et al. Local Failure (LF) of Osteosarcoma (OS): Risk Factors and Prognosis. Results of the Cooperative OS Study Group COSS. Proc. Am. Soc. Clin. Oncol. 1996; 15: 520, (abstract 1674)
   Google Scholar
• Bacci G., Ferrari S., Longhi A., et al. Local Recurrence (L) in Non-Metastatic Osteosarcoma of the Extremities (OE) Treated with Neoadjuvant Chemotherapy (NC)—the Rizzoli Experience. Proc. Am. Soc. Clin. Oncol. 1997; 16: 496a, (abstract 1786)
   Google Scholar
• Glasser D. B., Lane J. M. Stage IIB Osteogenic Sarcoma. Clin. Orthop. 1991; 270: 29–39
   PubMed Web of Science ®Google Scholar
• Bacci G., Ferrari S., Mercuri M., et al. Predictive Factors for Local Recurrence in Osteosarcoma: 540 Patients with Extremity Tumors Followed for Minimum 2.5 Years After Neoadjuvant Chemotherapy. Acta Orthop. Scand. 1998; 69: 230–236
   PubMed Web of Science ®Google Scholar
• Babin S. R., Simon P., Babin-Boilletot A., et al. Can Amputation Be Avoided in Local Recurrence After Limb Salvage for High Grade Osteosarcoma? A Case Report and a Review of the Literature. Int. Orthop. 1995; 19: 374–376
   PubMed Web of Science ®Google Scholar
• Rougraff B. T., Simon M. A., Kneisl J. S., et al. Limb Salvage Compared with Amputation for Osteosarcoma of the Distal End of the Femur. A Long-Term Oncological, Function, and Quality-of-Life Study. J. Bone Joint Surg. [Am.] 1994; 76: 649–656
   PubMed Web of Science ®Google Scholar
• Greenberg D. B., Goorin A., Gebhardt M. C., et al. Quality of Life in Osteosarcoma Survivors. Oncology (Huntingt.) 1994; 8: 19–25
   PubMedGoogle Scholar
• Abudu A., Sferopoulos N. K., Tillman R. M., et al. The Surgical Treatment and Outcome of Pathologic Fractures in Localized Osteosarcoma. J. Bone Joint Surg. [Br.] 1996; 78: 694–698
   PubMedGoogle Scholar
• Jaffe N., Spears R., Eftekhari F., et al. Pathologic Fracture in Osteosarcoma. Impact of Chemotherapy on Primary Tumor and Survival. Cancer 1987; 59: 701–709
   PubMed Web of Science ®Google Scholar
• Hirano T., Iwasaki K., Kumashiro T., et al. Encapsulation around Malignant Bone Tumors After Preoperative Adjuvant Treatment. Nippon Seikeigeka Gakkai Zasshi 1992; 66: 31–37
   PubMedGoogle Scholar
• Yip K. M., Leung P. C., Kumta S. M. Osteosarcoma in Hong Kong. Clin. Orthop. 1996; 323: 49–59
   PubMedGoogle Scholar
• Cohen I. J., Kaplinsky C., Katz K., et al. Improved Results in Osteogenic Sarcoma 1973–79 vs. 1980–86: Analysis of Results from a Single Center. Isr. J. Med. Sci. 1993; 29: 27–29
   PubMedGoogle Scholar
• Gebhardt M. C., Flugstad D. I., Springfield D. S., et al. The Use of Bone Allografts for Limb Salvage in High-Grade Extremity Osteosarcoma. Clin. Orthop. 1991; 270: 181–196
   PubMed Web of Science ®Google Scholar
• Mankin H. J., Springfield D. S., Gebhardt M. C., et al. Current Status of Allografting for Bone Tumors. Orthopedics 1992; 15: 1147–1154
   PubMed Web of Science ®Google Scholar
• Huckstep R. L., Sherry E. Replacement of the Proximal Humerus in Primary Bone Tumors. Aust. N.Z. J. Surg. 1996; 66: 97–100
   PubMedGoogle Scholar
• Mankin H. J., Gebhardt M. C., Jennings L. C., et al. Long-Term Results of Allograft Replacement in the Management of Bone Tumors. Clin. Orthop. 1996; 324: 86–97
   PubMed Web of Science ®Google Scholar
• Abudu A., Carter S. R., Grimer R. J. The Outcome and Functional Results of Diaphyseal Endoprostheses After Tumour Excision. J. Bone Joint Surg. [Br.] 1996; 78: 652–657
   PubMedGoogle Scholar
• Ortiz-Cruz E., Gebhardt M. C., Jennings L. C. The Results of Transplantation of Intercalary Allografts After Resection of Tumors. A Long-Term Follow-Up Study. J. Bone Joint Surg. [Am.] 1997; 79: 97–106
   PubMed Web of Science ®Google Scholar
• Jofe M. H., Gebhardt M. C., Tomford W. W., et al. Reconstruction for Defects of the Proximal Part of the Femur Using Allograft Arthroplasty. J. Bone Joint Surg. [Am.] 1988; 70: 507–516
   PubMed Web of Science ®Google Scholar
• Schiller C., Windhager R., Fellinger E. J., et al. Extendable Tumour Endoprostheses for the Leg in Children. J. Bone Joint Surg. [Br.] 1995; 77: 608–614
   PubMedGoogle Scholar
• Jaffe N., Pearson P., Smith T., et al. Limb Salvage in Pediatric Osteosarcoma: Complications of Prosthetic Replacement and Duration of Function. Proc. Am. Soc. Clin. Oncol. 1998; 17: 535a, (abstract 2055)
   Google Scholar
• Tomford W. W., Bloem R. M., Mankin H. J. Osteoarticular Allografts. Acta Orthop. Belg. 1991; 57(suppl2)98–102
   PubMedGoogle Scholar
• Simon M. A. Limb Salvage for Osteosarcoma in the 1980s. Clin. Orthop. 1991; 270: 264–270
   PubMedGoogle Scholar
• Clohisy D. R., Mankin H. J. Osteoarticular Allografts for Reconstruction After Resection of a Musculoskeletal Tumor in the Proximal End of the Tibia. J. Bone Joint Surg. [Am.] 1994; 76: 549–554
   PubMedGoogle Scholar
• Berrey B. H., Jr., Lord C. F., Gebhardt M. C., et al. Fractures of Allografts. Frequency, Treatment, and End-Results. J. Bone Joint Surg. [Am.] 1990; 72: 825–833
   PubMedGoogle Scholar
• Lord C. F., Gebhardt M. C., Tomford W. W., et al. Infection in Bone Allografts. Incidence, Nature, and Treatment. J. Bone Joint Surg. [Am.] 1988; 70: 369–376
   PubMed Web of Science ®Google Scholar
• Shea K. G., Coleman D. A., Scott S. M., et al. Microvascularized Free Fibular Grafts for Reconstruction of Skeletal Defects after Tumor Resection. J. Pediatr. Orthop. 1997; 17: 424–432
   PubMed Web of Science ®Google Scholar
• Wozniak W., Izbicki T., Rychlowska M., et al. Malignant Humeral Bone Tumors in Children: Excision and Reconstruction with the Use of Rotated Clavicle. J. Surg. Oncol. 1996; 62: 183–185
   PubMed Web of Science ®Google Scholar
• Salzer M., Knahr K., Kotz R., et al. Treatment of Osteosarcoma of the Distal Femur by Rotation-Plasty. Arch. Orthop. Trauma Surg. 1981; 99: 131–136
   PubMed Web of Science ®Google Scholar
• Kotz R., Salzer M. Rotation-Plasty for Childhood Osteosarcoma of the Distal Part of the Femur. J. Bone Joint Surg. [Am.] 1982; 64: 959–969
   PubMed Web of Science ®Google Scholar
• Merkel K. D., Gebhardt M., Springfield D. S. Rotationplasty as a Reconstructive Operation After Tumor Resection. Clin. Orthop. 1991; 270: 231–236
   PubMedGoogle Scholar
• Gottsauner-Wolf F., Koptz R., Knahr K., et al. Rotationplasty for Limb Salvage in the Treatment of Malignant Tumors at the Knee. A Follow-Up Study of Seventy Patients. J. Bone Joint Surg. [Am.] 1991; 73: 1365–1375
   PubMed Web of Science ®Google Scholar
• Kotz R. Rotationplasty Semin. Surg. Oncol. 1997; 13: 34–40
   Google Scholar
• Beck J. C., Wara W. M., Bovill E. G., Jr., et al. The Role of Radiation Therapy in the Treatment of Osteosarcoma. Radiology 1976; 120: 163–165
   PubMed Web of Science ®Google Scholar
• Berg N. O., Hakansson C. H., Lovdahl R., et al. Radiotherapy and Surgery in 50 Cases of Osteosarcoma Treated Without Adjuvant Chemotherapy. Acta Orthop. Scand. 1977; 48: 580–585
   PubMed Web of Science ®Google Scholar
• Lombardi F., Gandola L., Fossati-Bellani F., et al. Hypofractionated Accelerated Radiotherapy in Osteogenic Sarcoma. Int. J. Radiat. Oncol. Biol. Phys. 1992; 24: 761–765
   PubMed Web of Science ®Google Scholar
• Newton K. A., Barrett A. Prophylactic Lung Irradiation in the Treatment of Osteogenic Sarcoma. Clin. Radiol. 1978; 29: 493–496
   PubMed Web of Science ®Google Scholar
• Caceres E., Zaharia M., Moran M., et al. Adjuvant Whole-Lung Radiation with or Without Adriamycin Treatment in Osteogenic Sarcoma. Cancer Treat. Rep. 1978; 62: 297–299
   PubMedGoogle Scholar
• Breur K., Schweisguth O., Cohen P., et al. C Prophylactic Irradiation of the Lungs to Prevent Development of Pulmonary Metastases in Patients with Osteosarcoma of the Limbs. J. Natl. Cancer Inst. Monogr. 1981; 56: 233–236
   Google Scholar
• Trifaud G., Jasmin C. Adjuvant Therapy of Osteogenic Osteosarcomas of the Limb: Results of the S04 78 Trial. Semin. Hop. 1982; 58: 1749–1753
   PubMedGoogle Scholar
• Jasmin C. A Strategic Adjuvant Therapy of Osteosarcoma. Recent Results Cancer Res. 1982; 80: 108–114
   PubMedGoogle Scholar
• Zaharia M., Caceres E., Valdivia S., et al. Postoperative Whole Lung Irradiation with or Without Adriamycin in Osteogenic Sarcoma. Int. J. Radiat. Oncol. Biol. Phys. 1986; 12: 907–910
   PubMed Web of Science ®Google Scholar
• Rab G. T., Ivins J. C., Childs D. S., Jr., et al. Elective Whole Lung Irradiation in the Treatment of Osteogenic Sarcoma. Cancer 1976; 38: 939–942
   PubMed Web of Science ®Google Scholar
• Jenkin R. D. Radiation Treatment of Ewing’s Sarcoma and Osteogenic Sarcoma. Can. J. Surg. 1977; 20: 530–536
   PubMed Web of Science ®Google Scholar
• Kuhl J., Richter E., Wunsch P. H., et al. Local Radiotherapy Combined with Systemic Chemotherapy in 3 Children with Osteosarcoma of an Extremity. Klin. Padiatr. 1986; 198: 267–270
   PubMedGoogle Scholar
• Ivins J. C., Taylor W. F., Wold L. E. Elective Whole-Lung Irradiation in Osteosarcoma Treatment: Appearance of Bilateral Breast Cancer in Two Long-Term Survivors. Skeletal Radiol. 1987; 16: 133–135
   PubMed Web of Science ®Google Scholar
• Smeele L. E., Kostense P. J., van der Waal I, et al. Effect of Chemotherapy on Survival of Craniofacial Osteosarcoma: A Systematic Review of 201 Patients. J. Clin. Oncol. 1997; 15: 363–367
   PubMed Web of Science ®Google Scholar
• Thompson D. K., Li F. P., Cassady J. R. Breast Cancer in a Man 30 Years After Radiation for Metastatic Osteogenic Sarcoma. Cancer 1979; 44: 2362–2365
   PubMed Web of Science ®Google Scholar
• Ellis E. R., Marcus R. B., Jr., Cicale M. J., et al. Pulmonary Function Tests After Whole-Lung Irradiation and Doxorubicin in Patients with Osteogenic Sarcoma. J. Clin. Oncol. 1992; 10: 459–463
   PubMed Web of Science ®Google Scholar
• Stea B., Cavazzana A., Kinsella T. J. Small-Cell Osteosarcoma: Correlation of In Vitro and Clinical Radiation Response. Int. J. Radiat. Oncol. Biol. Phys. 1988; 15: 1233–1238
   PubMed Web of Science ®Google Scholar
• Goffinet D. R., Kaplan H. S., Donaldson S. S., et al. Combined Radiosensitizer Infusion and Irradiation of Osteogenic Sarcomas. Radiology 1975; 117: 211–214
   PubMed Web of Science ®Google Scholar
• Astrada-Aguilar J., Greenberg H., Walling A., et al. Primary Treatment of Pelvic Osteosarcoma. Report of Five Cases. Cancer 1992; 69: 1137–1145
   PubMed Web of Science ®Google Scholar
• Hug E. B., Fitzek M. M., Liebsch N. J., et al. Locally Challenging Osteo- and Chondrogenic Tumors of the Axial Skeleton: Results of Combined Proton and Photon Radiation Therapy Using Three-Dimensional Treatment Planning. Int. J. Radiat. Oncol. Biol. Phys. 1995; 31: 467–476
   PubMed Web of Science ®Google Scholar
• Hershey A., Bos G. D., Stevens K. Successful Treatment of Spinal Osteosarcoma with Radiation and Chemotherapy. Orthopedics 1996; 19: 617–618
   PubMed Web of Science ®Google Scholar
• Shibamoto Y., Ohshio G., Hosotani R., et al. A Phase I/II Study of a Hypoxic Cell Radiosensitizer KU-2285 in Combination with Intraoperative Radiotherapy. Cancer 1997; 76: 1474–1479
   Web of Science ®Google Scholar
• Isacsson U., Hagberg H., Johansson K. A., et al. Potential Advantages of Protons over Conventional Radiation Beams for Paraspinal Tumours. Radiother. Oncol. 1997; 45: 63–70
   PubMed Web of Science ®Google Scholar
• Carrie C., Breteau N., Negrier S., et al. The Role of Fast Neutron Therapy in Unresectable Pelvic Osteosarcoma: Preliminary Report. Med. Pediatr. Oncol. 1994; 22: 355–357
   PubMedGoogle Scholar
• Chauvel P. Osteosarcomas and Adult Soft Tissue Sarcomas: Is There a Place for High LET Radiation Therapy?. Ann. Oncol. 1992; 3(suppl 2)S107–S110
   PubMedGoogle Scholar
• Banelli E., Zurlo A., Donato V., et al. Radiotherapy of Bone Tumors. Analysis of a Historic Series and Review of the Literature. Radiol. Med. (Torino) 1997; 93: 115–122
   PubMedGoogle Scholar
• Goffman T., Tochner Z., Glatstein E. Primary Treatment of Large and Massive Adult Sarcomas with Iododeoxyuridine and Aggressive Hyperfractionated Irradiation. Cancer 1991; 67: 572–576
   PubMed Web of Science ®Google Scholar
• Calvo F. A., Ortiz de Urbina D., Sierrasesumuga L., et al. Intraoperative Radiotherapy in the Multidisciplinary Treatment of Bone Sarcomas in Children and Adolescents. Med. Pediatr. Oncol. 1991; 19: 478–485
   PubMedGoogle Scholar
• Van Putten L. M., Smink T. Misonidazole with Small Dose Fractions in an Experimental Osteosarcoma. Br. J. Cancer 1978; 37(suppl)246–249
   Google Scholar
• Bruland O. S., Skretting A., Solheim O. P., et al. Targeted Radiotherapy of Osteosarcoma Using 153Sm-EDTMP. A New Promising Approach. Acta Oncol. 1996; 35: 381–384
   PubMed Web of Science ®Google Scholar
• Winderen M., Kjonniksen I., Fodstad O. Pronounced Therapeutic Effect of Samarium 153-Ethylenediaminetetramethylene Phosphonate in an Orthotopic Human Osteosarcoma Tibial Tumor Model. J. Natl. Cancer Inst. 1995; 87: 221–222
   PubMed Web of Science ®Google Scholar
• Larsen R. H., Bruland O. S., Hoff P., et al. Inactivation of Human Osteosarcoma Cells In Vitro by 211At-TP-3 Monoclonal Antibody: Comparison with Astatine-211-Labeled Bovine Serum Albumin, Free Astatine-211 and External-Beam X Rays. Radiat. Res. 1994; 139: 178–184
   PubMed Web of Science ®Google Scholar
• Larsen R. H., Bruland O. S., Hoff P., et al. Analysis of the Therapeutic Gain in the Treatment of Human Osteosarcoma Microcolonies In Vitro with 211At-Labelled Monoclonal Antibody. Br. J. Cancer 1994; 69: 1000–1005
   PubMed Web of Science ®Google Scholar
• Rosenburg S. A., Flye M. W., Conkle D., et al. Treatment of Osteogenic Sarcoma. II. Aggressive Resection of Pulmonary Metastases. Cancer Treat. Rep. 1979; 63: 753–756
   PubMedGoogle Scholar
• al-Jilaihawi A. N., Bullmore J., Mott M., et al. Combined Chemotherapy and Surgery for Pulmonary Metastases from Osteogenic Sarcoma. Results of 10 Years Experience. Eur. J. Cardiothorac. Surg. 1988; 2: 37–42
   PubMedGoogle Scholar
• Ellis P. M., Tattersall M. H., McCaughan B., et al. Osteosarcoma and Pulmonary Metastases: 15-Year Experience from a Single Institution. Aust. NZ J. Surg. 1997; 67: 625–629
   PubMedGoogle Scholar
• Morgan E., Baum E., Bleyer W. A., et al. Treatment of Patients with Metastatic Osteogenic Sarcoma: A Report from the Children’s Cancer Study Group. Cancer Treat. Rep. 1984; 68: 661–664
   PubMedGoogle Scholar
• Tabone M. D., Kalifa C., Rodary C., et al. Osteosarcoma Recurrences in Pediatric Patients Previously Treated with Intensive Chemotherapy. J. Clin. Oncol. 1994; 12: 2614–2620
   PubMed Web of Science ®Google Scholar
• Babin S. R., Simon R., Babin-Boilletot A., et al. Can Amputation Be Avoided in Local Recurrence After Limb Salvage for High Grade Osteosarcoma? A Case Report and a Review of the Literature. Int. Orthop. 1995; 19: 374–376
   PubMed Web of Science ®Google Scholar